SCHEMBL1847445

SCHEMBL1847445

CC(=O)OC[C@H]1OC(n2cnc(N)nc2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ TP53 P04637 2/20 0.61
▸ MAPT P10636 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ THRB P10828 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ DNMT1 P26358 2/20 0.52
▸ GMNN O75496 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ THPO P40225 1/20 0.52
▸ MTOR P42345 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ HBB P68871 1/20 0.52
▸ PMP22 Q01453 1/20 0.52
▸ PRKAB2 O43741 1/20 0.49
▸ PRKAG1 P54619 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1433826 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13019177 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL19059876 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL21835519 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL1847443 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL15689845 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13243124 1.00 LMNA (0.61) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL14146164 0.91 ALDH1A1 (0.52) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL11794055 0.91 LMNA (0.58) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL15702571 0.91 ALDH1A1 (0.63) LMNAALDH1A1TP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130008238-A1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE BIGATTI ETTORE (IT) 2013-01-10 — — US disclosed
EP-2324042-B1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE SICOR INC (US) 2012-11-28 — — EP disclosed
EP-2520581-A1 Method for the determination the purity of 5-Azacytidine Sicor, Inc. (US) 2012-11-07 — — EP disclosed
EP-2324042-A1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE Sicor, Inc. (US) 2011-05-25 — — EP disclosed
WO-2010017374-A1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE SICOR INC. (US) 2010-02-11 — — WO disclosed
US-20100035354-A1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE SICOR INC. 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035354-A1 PROCESS FOR PREPARING AZACYTIDINE INTERMEDIATE TET2, AZI2, DNMT1 LMNA 1206/4885ALDH1A1 481/4885TP53 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback